KURA Kura Oncology, Inc.
$9.90▲ +2.91%
Healthcare
Other
After hours
$9.94▲ +0.41%
Oct 27, 4:56 PM ET
Volume 1.71M
Avg Volume (10D) 1.63M
Key Metrics & Fundamentals
Market Cap
$880.71M
P/E Ratio
–
Div Yield
0.00%
52W Range
7.36 - 13.90
% vs 50 MA
-12.03%
% vs 200 MA
1.15%
RSI-14
43.5
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.31
Free Cash Flow
-$63.21M
Gross Rev
$20.87M
Gross Profit
$20.63M
EBITDA
-$67.61M
COGS
$243,000
Operating Exp
$93.64M
Operating Income
-$73.01M
EBIT
-$73.01M
Pretax Income
-$68.32M
Net Income
-$68.33M
EPS (Diluted)
-0.77
Price & Volume History
Loading chart…
Recent News
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Zacks · Oct 27, 2026 9:00 AM ET
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
MarketBeat · Oct 13, 2026 8:02 PM ET
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
GlobeNewswire · Oct 13, 2026 7:30 AM ET
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
GlobeNewswire · Oct 7, 2026 7:15 AM ET
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 7:30 AM ET
Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors
GlobeNewswire · Oct 1, 2026 7:02 AM ET
JPMorgan Initiates Kura Oncology at Overweight With $30 Price Target
MT Newswires · Oct 1, 2026 5:45 AM ET
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
GlobeNewswire · Sep 29, 2026 5:15 AM ET
Kura spins diabetes work into a Lilly-backed biotech startup
BioPharma Dive · Sep 9, 2026 11:54 AM ET
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Benzinga · Sep 9, 2026 9:57 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See KURA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.